Evidence map›Paper›PMID 38807192›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

Protein homeostasis maintained by HOOK1 levels promotes the tumorigenic and stemness properties of ovarian cancer cells through reticulum stress and autophagy.

Elisa Suárez-Martínez, Sander R Piersma, Thang V Pham, Irene V Bijnsdorp, Connie R Jimenez, Amancio Carnero

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elisa Suárez-MartínezInstituto de Biomedicina de Sevilla (IBIS), HUVR/CSIC/Universidad de Sevilla, Avda. Manuel Siurot S/N; Campus HUVR, Ed. IBIS,, Seville, 41013, Spain.
Sander R PiersmaOncoProteomics Laboratory, VUmc-Cancer Center Amsterdam, VU University Medical Center, CCA 1-60, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands.
Thang V PhamOncoProteomics Laboratory, VUmc-Cancer Center Amsterdam, VU University Medical Center, CCA 1-60, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands.
Irene V BijnsdorpOncoProteomics Laboratory, VUmc-Cancer Center Amsterdam, VU University Medical Center, CCA 1-60, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands.
Connie R JimenezOncoProteomics Laboratory, VUmc-Cancer Center Amsterdam, VU University Medical Center, CCA 1-60, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands.
Amancio CarneroInstituto de Biomedicina de Sevilla (IBIS), HUVR/CSIC/Universidad de Sevilla, Avda. Manuel Siurot S/N; Campus HUVR, Ed. IBIS,, Seville, 41013, Spain. acarnero-ibis@us.es.ORCID http://orcid.org/0000-0003-4357-3979

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer has a high mortality rate mainly due to its resistance to currently used therapies. This resistance has been associated with the presence of cancer stem cells (CSCs), interactions with the microenvironment, and intratumoral heterogeneity. Therefore, the search for new therapeutic targets, particularly those targeting CSCs, is important for improving patient prognosis. HOOK1 has been found to be transcriptionally altered in a substantial percentage of ovarian tumors, but its role in tumor initiation and development is still not fully understood.

methodsThe downregulation of HOOK1 was performed in ovarian cancer cell lines using CRISPR/Cas9 technology, followed by growth in vitro and in vivo assays. Subsequently, migration (Boyden chamber), cell death (Western-Blot and flow cytometry) and stemness properties (clonal heterogeneity analysis, tumorspheres assay and flow cytometry) of the downregulated cell lines were analysed. To gain insights into the specific mechanisms of action of HOOK1 in ovarian cancer, a proteomic analysis was performed, followed by Western-blot and cytotoxicity assays to confirm the results found within the mass spectrometry. Immunofluorescence staining, Western-blotting and flow cytometry were also employed to finish uncovering the role of HOOK1 in ovarian cancer.

resultsIn this study, we observed that reducing the levels of HOOK1 in ovarian cancer cells reduced in vitro growth and migration and prevented tumor formation in vivo. Furthermore, HOOK1 reduction led to a decrease in stem-like capabilities in these cells, which, however, did not seem related to the expression of genes traditionally associated with this phenotype. A proteome study, along with other analysis, showed that the downregulation of HOOK1 also induced an increase in endoplasmic reticulum stress levels in these cells. Finally, the decrease in stem-like properties observed in cells with downregulated HOOK1 could be explained by an increase in cell death in the CSC population within the culture due to endoplasmic reticulum stress by the unfolded protein response.

conclusionHOOK1 contributes to maintaining the tumorigenic and stemness properties of ovarian cancer cells by preserving protein homeostasis and could be considered an alternative therapeutic target, especially in combination with inducers of endoplasmic reticulum or proteotoxic stress such as proteasome inhibitors.

Indexed as

AutophagyEndoplasmic Reticulum StressNeoplastic Stem CellsOvarian NeoplasmsProteostasisAnimalsCell Line, TumorCell MovementCell ProliferationFemaleHumansMiceMicrotubule-Associated ProteinsMicrotubule-Associated ProteinsER stressHOOK1Ovarian cancerStemness

Identifiers

PMID38807192
PMCPMC11134651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.